Journal article · 2025 · Open access

Optimizing the Banking and Releasing Strategies of Clinical‐Grade HLA‐Homozygous Human iPSCs for Regenerative Medicine

Qianping Zhang, Lijuan Cui, Ying Jia, Xiaohui Shi, Jinmei Zhang, Li Zhang, Zhihui Liu, Yun Zhang, Haidong Fu, Qi Qi, Quan Chen, Wei Du and 1 more

Stem Cells International, 2025(1), 3010753 · Published 1 January 2025 · DOI 10.1155/sci/3010753

Open PDFView at the publisherCite this paper

In brief

“Optimizing the Banking and Releasing Strategies of Clinical‐Grade HLA‐Homozygous Human iPSCs for Regenerative Medicine” is a 2025 journal article by Qianping Zhang and 12 co-authors, published in Stem Cells International. OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Stem Cells International.

Citations
0
References
31
Authors
13

Abstract

Since their initial generation, induced pluripotent stem cells (iPSCs) have attracted considerable attention and undergone rapid development. iPSC‐derived cell therapies show great promise in the field of regenerative medicine. However, their clinical translation faces two major challenges: the limited availability of good manufacturing practice (GMP)‐compliant human iPSC (hiPSC) lines, and the high costs and prolonged timelines associated with autologous hiPSC‐based therapies. Allogeneic therapies based on rigorously quality‐controlled, GMP‐compliant, human leukocyte antigen (HLA)‐homozygous hiPSCs thus represent a promising alternative. In this study, we established and validated a GMP‐compliant platform for iPSCs production, complete with a comprehensive set of standard operating procedures (SOPs) and recommended release criteria for the iPSC master cell bank (MCB). Using frozen umbilical cord blood (UCB) from donors with high‐frequency HLA homozygosity as starting material, we generated five monoclonal iPSC MCB lines and performed full release testing. Among the five iPSC lines, three demonstrated high post‐thaw survival rates, met all release criteria, and exhibited strong potential for multilineage differentiation and clinical application in cell therapy.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Zhang, Q., Cui, L., Jia, Y., Shi, X., Zhang, J., Zhang, L., Liu, Z., Zhang, Y., Fu, H., Qi, Q., Chen, Q., Du, W., & Zhang, Y. (2025). Optimizing the Banking and Releasing Strategies of Clinical‐Grade HLA‐Homozygous Human iPSCs for Regenerative Medicine. Stem Cells International, 2025(1), 3010753. https://doi.org/10.1155/sci/3010753

MLA 9

Zhang, Qianping, et al. “Optimizing the Banking and Releasing Strategies of Clinical‐Grade HLA‐Homozygous Human iPSCs for Regenerative Medicine.” Stem Cells International, vol. 2025, no. 1, 2025, p. 3010753. https://doi.org/10.1155/sci/3010753.

Chicago

Zhang, Qianping, Lijuan Cui, Ying Jia, Xiaohui Shi, Jinmei Zhang, Li Zhang, Zhihui Liu, et al. 2025. “Optimizing the Banking and Releasing Strategies of Clinical‐Grade HLA‐Homozygous Human iPSCs for Regenerative Medicine.” Stem Cells International 2025 (1): 3010753. https://doi.org/10.1155/sci/3010753.

Harvard

Zhang, Q. et al. (2025) ‘Optimizing the Banking and Releasing Strategies of Clinical‐Grade HLA‐Homozygous Human iPSCs for Regenerative Medicine’, Stem Cells International, 2025(1), p. 3010753. doi:10.1155/sci/3010753.

IEEE

Q. Zhang et al., “Optimizing the Banking and Releasing Strategies of Clinical‐Grade HLA‐Homozygous Human iPSCs for Regenerative Medicine,” Stem Cells International, vol. 2025, no. 1, p. 3010753, 2025, doi: 10.1155/sci/3010753.

BibTeX

@article{zhang2025optimizing,
  title     = {{Optimizing the Banking and Releasing Strategies of Clinical‐Grade HLA‐Homozygous Human iPSCs for Regenerative Medicine}},
  author    = {Zhang, Qianping and Cui, Lijuan and Jia, Ying and Shi, Xiaohui and Zhang, Jinmei and Zhang, Li and Liu, Zhihui and Zhang, Yun and Fu, Haidong and Qi, Qi and Chen, Quan and Du, Wei and Zhang, Yu},
  journal   = {Stem Cells International},
  year      = {2025},
  volume    = {2025},
  number    = {1},
  pages     = {3010753},
  doi       = {10.1155/sci/3010753},
  url       = {https://doi.org/10.1155/sci/3010753}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research

  • induced pluripotent stem cells
  • master cell bank
  • cell banking
  • allogeneic cell therapy
  • umbilical cord blood
  • post-thaw survival
  • multilineage differentiation
  • standard operating procedures

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Zhang, Q., Cui, L., Jia, Y., Shi, X., Zhang, J., Zhang, L., Liu, Z., Zhang, Y., Fu, H., Qi, Q., Chen, Q., Du, W., & Zhang, Y. (2025). Optimizing the Banking and Releasing Strategies of Clinical‐Grade HLA‐Homozygous Human iPSCs for Regenerative Medicine. Stem Cells International, 2025(1), 3010753. https://doi.org/10.1155/sci/3010753

How many times has this paper been cited?

0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Stem Cells International: sign in and open the PDF from this page.

Who wrote this paper?

Qianping Zhang, Lijuan Cui, Ying Jia, Xiaohui Shi, Jinmei Zhang, Li Zhang, Zhihui Liu, Yun Zhang, Haidong Fu, Qi Qi, Quan Chen, Wei Du and 1 more.

What is the DOI of this paper?

10.1155/sci/3010753, permanently at https://doi.org/10.1155/sci/3010753. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.